Latest Breaking News On - Salariu phase - Page 1 : comparemela.com

Salarius Pharmaceuticals (SLRX) Issues Update on Strategic Review Process, Will Support Ongoing Seclidemstat Clinical Trials by Further Cost Cuts

Salarius Pharmaceuticals (SLRX) Issues Update on Strategic Review Process, Will Support Ongoing Seclidemstat Clinical Trials by Further Cost Cuts
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

William mcvicarDavid arthurSalarius pharmaceuticals incCanaccord genuityMd anderson cancer centerSalarius pharmaceuticalsCancer centerSalariu phaseChief executive officer

Salarius Pharmaceuticals (SLRX) Announces FDA Removal of Clinical Hold on Seclidemstat Trial

Salarius Pharmaceuticals (SLRX) Announces FDA Removal of Clinical Hold on Seclidemstat Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

David arthurSalarius pharmaceuticalsUniversity of texas md anderson cancer centerSalarius pharmaceuticals incDrug administration typeCanaccord genuityCancer centerSalariu phaseCompany sponsored ewing

Salarius (SLRX) Announces FDA Removes Partial Clinical Hold on Phase 1/2 Trial of Seclidemstat

Salarius (SLRX) Announces FDA Removes Partial Clinical Hold on Phase 1/2 Trial of Seclidemstat
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Sankt peterburgNew yorkUnited statesDana farber cancer instituteFox chase cancer centerMemorial sloan kettering cancer centerRelationskim sutton golodetzDavid arthurLos angelesInternational conventionProduct development awardWashington university in stOregon health sciences university in portlandSalarius pharmaceuticalssalarius pharmaceuticals incSalarius pharmaceuticals incResearch institute of texas

Salarius Pharmaceuticals, Inc : Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Data to be presented at AACR demonstrate significant SP-3164 anticancer activity in both non-Hodgkin Lymphoma and Multiple Myeloma cell lines and animal models Targeted protein degrader SP-3164 on track

United statesDavid arthurKim sutton golodetzDrug administrationProduct development awardExchange commissionSalarius pharmaceuticals incAmerican association for cancer researchAmerican society of hematology annual meetingSalarius pharmaceuticalsAmerican society of hematologyMd anderson cancer centerResearch institute of texasNational pediatric cancer foundationUniversity of texas md andersonHodgkin lymphoma

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesRelationskim sutton golodetzDavid arthurMd anderson cancer centerProduct development awardSalarius pharmaceuticals incAmerican association for cancer researchUniversity of texas md andersonSalarius pharmaceuticalssalarius pharmaceuticals incAmerican society of hematologyExchange commissionResearch institute of texasNational pediatric cancer foundationDrug administrationAmerican society of hematology annual meetingHodgkin lymphoma